Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.

Ramirez-Valdez RA. et al, (2023), Cell reports, 42

Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1.

Peng R. et al, (2022), EMBO reports, 23

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.

Leung CSK. and Van den Eynde BJ., (2022), Cancer cell, 40, 903 - 905

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

McAuliffe J. et al, (2021), Journal for immunotherapy of cancer, 9

ZBP1 induces inflammatory signaling via RIPK3 and promotes SARS-CoV-2-induced cytokine expression

Peng R. et al, (2021)

Vaccination against the Epstein-Barr virus.

Rühl J. et al, (2020), Cellular and molecular life sciences : CMLS, 77, 4315 - 4324

Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.

Rühl J. et al, (2019), The Journal of clinical investigation, 129, 2071 - 2087

Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.

Leung CS., (2018), Journal of immunology research, 2018

Immunotherapy and Vaccine Development.

Leung C. et al, (2018), J Immunol Res, 2018

Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic Pathways.

Leung CSK., (2015), Frontiers in immunology, 6

Human Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection (vol 5, pg 1489, 2013)

Chijioke O. et al, (2015), CELL REPORTS, 12, 901 - 901

Animal models of Epstein Barr virus infection.

Chatterjee B. et al, (2014), Journal of immunological methods, 410, 80 - 87

Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.

Chijioke O. et al, (2013), Cell reports, 5, 1489 - 1498

Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral IRF3 Modulates Major Histocompatibility Complex Class II (MHC-II) Antigen Presentation through MHC-II Transactivator-Dependent and -Independent Mechanisms: Implications for Oncogenesis

Zuo J. et al, (2013), Journal of Virology, 87, 5340 - 5350

Robust T-cell stimulation by Epstein-Barr virus–transformed B cells after antigen targeting to DEC-205

Leung CS. et al, (2013), Blood, 121, 1584 - 1594

Include forthcoming?

In this section